According to Siebert this is far from ideal. ‘Individuals in high-risk groups should be diagnosed at the point of care to offer the best chance of behavior modification, other prevention strategies and, where appropriate, treatment.’ Siebert went on to note that the speed of the point-of-care tests such as those of his business grows for syphilis are an essential and integral part of any and all prevention programs.In addition to ChemBio two FDA-approved rapid tests for the company that is developing the next generation of rapid STD tests using their patented dual path platform. The company will begin to test these new products in early 2010 and include a new rapid oral fluid HIV test, a unique combination screen and confirm the point-of-care test for syphilis, and a quick test oral fluids C.
It ‘a wonderful self-help book that doctors want to recommend to all their patients with irritable bowel syndrome. Includes instructions on how strategies of behavior therapy that most research has shown to be effective for the syndrome irritable bowel, said William E. Whitehead, Ph., University of North Carolina at Chapel Hill.
‘The new technology for the diagnosis of syphilis confirms an active, previously untreated cases of syphilis to the point of care, allowing physicians to begin treatment immediately,’ said Siebert.
‘Part of the challenge of treating a young person is to have a visit again to check for diagnostic review. During this waiting period, a patient may be sexually active with one or more partners, and contributing to the growing problem of disease sexually transmitted, ’said Larry Siebert, CEO ChemBio Diagnostics, a New York-based company that develops, manufactures and markets rapid tests for licenses.
Sexually spread continues to rise, with cases reported setting a new record in 2008, officials from the Centers for Disease Control recently reported. The CDC estimates that nearly 19 million new STD infections each year the event.
About half of them are young people between 15 and 24 years.